A. Stalenhoef

发表

Hyperlipoproteinemia enhances susceptibility to acute disseminated Candida albicans infection in low-density-lipoprotein-receptor-deficient mice

M. Netea, B. Kullberg, J. V. D. van der Meer, 1997, Infection and immunity.

Atorvastatin and simvastatin in patients on hemodialysis: effects on lipoproteins, C-reactive protein and in vivo oxidized LDL.

L. V. van Tits, A. Stalenhoef, J. M. van den Akker, 2003, Journal of nephrology.

Answers to Questions Posed During Daily Patient Care Are More Likely to Be Answered by UpToDate Than PubMed

Arjen Hoogendam, Pieter F de Vries Robbé, A. Stalenhoef, 2008, Journal of medical Internet research.

European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invit

Shah Ebrahim, Harry Hemingway, Silvia G Priori, 2007, European heart journal.

Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance

Shizuo Akira, L. Joosten, M. Netea, 2006, Nature Medicine.

Diagnosing familial hypercholesterolaemia: the relevance of genetic testing.

M. Trip, J. Kastelein, A. Stalenhoef, 2006, European Heart Journal.

Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia Published, JLR Papers in Press, December 1, 2004. DOI 10.1194/jlr.M400052-JLR200

J. Kastelein, L. V. van Tits, A. Stalenhoef, 2005, Journal of Lipid Research.

Oxidized LDL enhances pro-inflammatory responses of alternatively activated M2 macrophages: a crucial role for Krüppel-like factor 2.

L. Joosten, M. Netea, L. V. van Tits, 2011, Atherosclerosis.

The Importance of Written Information Packages in Support of Case-Finding Within Families at Risk for Inherited High Cholesterol

I. Mesters, A. Stalenhoef, H. V. Nieuwenhoff, 2006, Journal of Genetic Counseling.

The coffee diterpene cafestol increases plasma triacylglycerol by increasing the production rate of large VLDL apolipoprotein B in healthy normolipidemic subjects.

C. Packard, M. Katan, P. Demacker, 2001, The American journal of clinical nutrition.

Apolipoprotein E polymorphism influences lipid phenotypic expression, but not the low density lipoprotein subfraction distribution in familial combined hyperlipidemia.

P. Demacker, A. Stalenhoef, S. Bredie, 1996, Atherosclerosis.

Familial dysbetalipoproteinemia associated with apolipoprotein E3-Leiden in an extended multigeneration pedigree.

P. de Knijff, R. Frants, L. Havekes, 1991, The Journal of clinical investigation.

The story of PON1: how an organophosphate-hydrolysing enzyme is becoming a player in cardiovascular medicine.

L. V. van Tits, A. Stalenhoef, M. Roest, 2006, The Netherlands journal of medicine.

Influence of anti-tumour necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis

M. Netea, P. V. van Riel, J. Meer, 2004, Annals of the rheumatic diseases.

Carotid Atherosclerosis Progression in Familial Hypercholesterolemia Patients: A Pooled Analysis of the ASAP, ENHANCE, RADIANCE 1, and CAPTIVATE Studies

J. Kastelein, M. Bots, C. Ballantyne, 2010, Circulation. Cardiovascular imaging.

Improved measurement of low-density-lipoprotein susceptibility to copper-induced oxidation: application of a short procedure for isolating low-density lipoprotein.

P. Demacker, A. Stalenhoef, H. Kleinveld, 1992, Clinical chemistry.

Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia.

P. de Knijff, R. Frants, L. Havekes, 1990, Atherosclerosis.

Can we exclude the TXNIP gene as a candidate gene for familial combined hyperlipidemia?

H. Blom, A. Stalenhoef, J. de Graaf, 2006, American journal of medical genetics. Part A.

Thioredoxin interacting protein in Dutch families with familial combined hyperlipidemia

H. Blom, L. Kluijtmans, A. Stalenhoef, 2004, American journal of medical genetics. Part A.

Diagnosis of Familial Combined Hyperlipidemia Based on Lipid Phenotype Expression in 32 Families: Results of a 5-Year Follow-Up Study

J. Hendriks, P. Demacker, A. Stalenhoef, 2002, Arteriosclerosis, thrombosis, and vascular biology.

The benefit of statins in non-cardiac vascular surgery patients.

A. Stalenhoef, 2009, Journal of vascular surgery.

Effects of atorvastatin and vitamin E on lipoproteins and oxidative stress in dialysis patients: a randomised‐controlled trial

J. van der Palen, A. Stalenhoef, H. Bilo, 2005, Journal of internal medicine.

The effect of statin therapy on plasma high‐density lipoprotein cholesterol levels is modified by paraoxonase‐1 in patients with familial hypercholesterolaemia

J. Graaf, A. Stalenhoef, M. Roest, 2005, Journal of internal medicine.

Vitamin E and fatty acid intervention does not attenuate the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits.

P. Demacker, A. Stalenhoef, N. J. de Fouw, 1995, Arteriosclerosis, thrombosis, and vascular biology.

Oxidation resistance, oxidation rate, and extent of oxidation of human low-density lipoprotein depend on the ratio of oleic acid content to linoleic acid content: studies in vitamin E deficient subjects.

P. Demacker, A. Stalenhoef, A. Naber, 1993, Free radical biology & medicine.

Apolipoprotein E knock-out mice are highly susceptible to endotoxemia and Klebsiella pneumoniae infection.

M. Netea, K. V. van Dijk, J. Meer, 1999, Journal of lipid research.

Tolerability and effects of high doses acipimox as additional lipid-lowering therapy in familial hypercholesterolemia.

A. Stalenhoef, P. Stuyt, H. Kleinjans, 1998, The Netherlands journal of medicine.

EFFECTS OF SYNVINOLIN (MK-733) ON PLASMA LIPIDS IN FAMILIAL HYPERCHOLESTEROLAEMIA

A. Stalenhoef, D. Erkelens, J. Leuven, 1986, The Lancet.

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

J. Borén, S. Humphries, M. Taskinen, 2014, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

The relationship between cholesteryl ester transfer protein levels and risk factor profile in patients with familial hypercholesterolemia.

A. Zwinderman, J. Kastelein, A. Stalenhoef, 2004, Atherosclerosis.

Apolipoprotein E phenotypes, serum lipoproteins and apolipoproteins in angiographically assessed coronary heart disease.

J. Hendriks, P. Demacker, A. Stalenhoef, 1991, Scandinavian journal of clinical and laboratory investigation.

Effects of pioglitazone in familial combined hyperlipidaemia

A. Heerschap, C. Tack, J. Graaf, 2006, Journal of internal medicine.

Nonobese patients with familial combined hyperlipidemia are insulin resistant compared with their nonaffected relatives.

C. Tack, A. Stalenhoef, P. Smits, 1997, Arteriosclerosis, thrombosis, and vascular biology.

ADIPONECTIN MULTIMER DISTRIBUTION IN PATIENTS WITH FAMILIAL COMBINED HYPERLIPIDEMIA

A. Stalenhoef, T. Koenen, L. Vantits, 2008 .

Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment

J. Borén, S. Humphries, M. Taskinen, 2015, European heart journal.

[Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society].

J. Borén, S. Humphries, M. Taskinen, 2015, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

LDL-Apheresis Atherosclerosis Regression Study (LAARS). Effect of aggressive versus conventional lipid lowering treatment on coronary atherosclerosis.

J. Reiber, G. Uijen, T. van der Werf, 1996, Circulation.

Application and validation of a diagnostic algorithm for the atherogenic apoB dyslipoproteinemias

D. Swinkels, M. den Heijer, S. Holewijn, 2011, European journal of clinical investigation.

High-density lipoprotein cholesterol subfractions HDL2 and HDL3 are reduced in women with rheumatoid arthritis and may augment the cardiovascular risk of women with RA: a cross-sectional study

L. Joosten, P. V. van Riel, J. Fransen, 2012, Arthritis Research & Therapy.

Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects.

J. Hendriks, J. Graaf, P. Demacker, 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

Plasma Lipoproteins, Apolipoproteins, and Triglyceride Metabolism in Familial Hypertriglyceridemia

P. Demacker, A. Stalenhoef, J. Lutterman, 1986, Arteriosclerosis.

Metabolic studies in various forms of hypertriglyceridemia in man

A. Stalenhoef, 1982 .

Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients

M. Netea, P. V. van Riel, F. V. D. van den Hoogen, 2008, Annals of the rheumatic diseases.

Long-term experience (6 years) with simvastatin in patients with heterozygous familial hypercholesterolaemia.

A. Stalenhoef, A. Kroon, M. Mol, 1995, The Netherlands journal of medicine.

The efficacy and safety of pravastatin, compared to and in combination with bile acid binding resins, in familial hypercholesterolaemia

E. Muls, A. Stalenhoef, N. Hoogerbrugge, 1990, Journal of internal medicine.

The effects of simvastatin on serum lipoproteins in severe hypercholesterolaemia.

P. Demacker, A. Stalenhoef, M. Mol, 1990, The Netherlands journal of medicine.

Metabolic and genetic aspects of familial combined hyperlipidaemia with emphasis on low‐density lipoprotein heterogeneity

P. Demacker, A. Stalenhoef, S. Bredie, 1997, European journal of clinical investigation.

Severe hypercholesterolaemia: therapeutic goals and eligibility criteria for LDL apheresis in Europe

B. Paulweber, M. Eriksson, E. Sijbrands, 2010, Current opinion in lipidology.

Comparison of the measurement of lipids and lipoproteins versus assay of apolipoprotein B for estimation of coronary heart disease risk: a study in familial combined hyperlipidemia.

P. Demacker, A. Stalenhoef, S. Bredie, 2000, Atherosclerosis.

Remnant particles are the major determinant of an increased intima media thickness in patients with familial combined hyperlipidemia (FCH).

S. Holewijn, A. Stalenhoef, S. Bredie, 2007, Atherosclerosis.

Inherited susceptibility determines the distribution of dense low-density lipoprotein subfraction profiles in familial combined hyperlipidemia.

L. Kiemeney, P. Demacker, A. Stalenhoef, 1996, American journal of human genetics.

Parabolic relationship between plasma triacylglycerols and LDL-cholesterol in familial combined hyperlipidaemia: the multiple-type hyperlipidaemia explained?

C. Stehouwer, C. V. D. van der Kallen, M. V. van Greevenbroek, 2008, Clinical science.

Efficacy of Concentrated n-3 Fatty Acids in Hypertriglyceridaemia

M. Prins, M. Trip, J. Kastelein, 2001, Clinical drug investigation.

The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia.

J. Kastelein, J. Kastelein, J. Graaf, 2000, Atherosclerosis.

Defects of lipoprotein metabolism in familial combined hyperlipidaemia.

J. Graaf, A. Stalenhoef, J. de Graaf, 1998, Current opinion in lipidology.

The redox status of coenzyme Q10 in total LDL as an indicator of in vivo oxidative modification. Studies on subjects with familial combined hyperlipidemia.

P. Demacker, A. Stalenhoef, S. Bredie, 1997, Arteriosclerosis, thrombosis, and vascular biology.

Effects of gemfibrozil or simvastatin on apolipoprotein-B-containing lipoproteins, apolipoprotein-CIII and lipoprotein(a) in familial combined hyperlipidaemia.

J. Kastelein, T. D. de Bruin, A. Stalenhoef, 1996, The Netherlands journal of medicine.

Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability.

J. Kastelein, J. Kastelein, T. D. de Bruin, 1995, The American journal of cardiology.

Identification of multiple dense LDL subfractions with enhanced susceptibility to in vitro oxidation among hypertriglyceridemic subjects. Normalization after clofibrate treatment.

J. Hendriks, J. Graaf, P. Demacker, 1993, Arteriosclerosis and thrombosis : a journal of vascular biology.

Single-spin density-gradient ultracentrifugation vs gradient gel electrophoresis: two methods for detecting low-density-lipoprotein heterogeneity compared.

D. Swinkels, J. Hendriks, P. Demacker, 1991, Clinical chemistry.

Differences in metabolism of three low density lipoprotein subfractions in Hep G2 cells.

D. Swinkels, J. Hendriks, P. Demacker, 1990, Biochimica et biophysica acta.

Journal of Medicine Elsevier Effects of Gemfibrozil or Simvastatin on Apolipoprotein-b-containing Lipoproteins, Apolipoprotein-ciii and Lipoproteint A) in Familial Combined Hyperlipidaemia

J. Kastelein, A. Stalenhoef, S. Bredie, 2022 .

PNMDEMACKER, RWB SCHADE, A F H STALENHOEF, P M J STUYT, Avan'tLAAR

P. Demacker, A. Stalenhoef, P. Stuyt, 2016 .

Influence of contraceptive pill and menstrual cycle on serum lipids and high-density lipoprotein cholesterol concentrations.

P. Demacker, A. Stalenhoef, A. van't Laar, 1982, British medical journal.

Catabolism of chylomicron remnants in normolipidemic subjects in relation to the apoprotein E phenotype.

P. Demacker, A. Stalenhoef, P. Stuyt, 1987, Journal of lipid research.

Effect of aggressive versus conventional lipid-lowering treatment on coronary and peripheral atherosclerosis: design and baseline characteristics of the LDL-Apheresis Atherosclerosis Regression Study (LAARS)

A. Stalenhoef, A. Kroon, 1996 .

Annexin A5 haplotypes in familial hypercholesterolemia: lack of association with carotid intima-media thickness and cardiovascular disease risk.

A. Stalenhoef, W. V. van Heerde, G. Dallinga-Thie, 2015, Atherosclerosis.

Annexin A 5 haplotypes in familial hypercholesterolemia : Lack of association with carotid intima-media thickness and cardiovascular disease risk

A. Stalenhoef, G. Dallinga-Thie, W. Heerde, 2014 .

HOMOZYGOUS AUTOSOMAL DOMINANT HYPERCHOLESTEROLEMIA IN THE NETHERLANDS: PREVALENCE, GENOTYPE-PHENOTYPE RELATIONSHIP AND CLINICAL OUTCOME

E. Sijbrands, J. Kastelein, J. Graaf, 2014 .

Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome.

E. Sijbrands, J. Kastelein, A. Stalenhoef, 2015, European heart journal.

The role of TNF- a in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk

M. Netea, J. Meer, A. Stalenhoef, 2007 .

Anti-inflammatory effects of troglitazone in nondiabetic obese subjects independent of changes in insulin sensitivity.

C. Sweep, C. Tack, L. V. van Tits, 2005, The Netherlands journal of medicine.

Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.

J. Kastelein, B. Imholz, F. Visseren, 2010, Atherosclerosis.

Casus 32 – Antwoord

A. Stalenhoef, J. D. Graaf, 2012 .

Comparative study on the effect of low-dose vitamin E and probucol on the susceptibility of LDL to oxidation and the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbits.

P. Demacker, A. Stalenhoef, H. Kleinveld, 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

Low Density Lipoprotein Apheresis Improves Regional Myocardial Perfusion in Patients With Hypercholesterolemia and Extensive Coronary Artery Disease

A. Stalenhoef, A. Kroon, W. Aengevaeren, 2019 .

Low density lipoprotein apheresis improves regional myocardial perfusion in patients with hypercholesterolemia and extensive coronary artery disease. LDL-Apheresis Atherosclerosis Regression Study (LAARS).

G. Uijen, T. van der Werf, A. Stalenhoef, 1996, Journal of the American College of Cardiology.

Effects of rosuvastatin on endothelial function in patients with familial combined hyperlipidaemia (FCH)

C. Tack, J. Graaf, S. Holewijn, 2005, Current medical research and opinion.

Efficacy, Safety and Tolerability of Simvastatin in Children with Familial Hypercholesterolaemia

M. Mercuri, J. Kastelein, A. Stalenhoef, 2002 .

Management of serum lipid levels into the next millennium: new targets for treatment.

A. Stalenhoef, 1999, The Netherlands journal of medicine.

Effect of lipid lowering therapy on myocardial perfusion; results from REGRESS and LAARS

G. Uijen, A. Stalenhoef, T. Werf, 1998 .

LPS-induced cytokine production and expression of LPS-receptors by peripheral blood mononuclear cells of patients with familial hypercholesterolemia and the effect of HMG-CoA reductase inhibitors.

M. Netea, J. V. D. van der Meer, P. Demacker, 1998, Atherosclerosis.

Effects of Peritoneal Dialysis with an Overnight Icodextrin Dwell on Parameters of Glucose and LIPID Metabolism

F. Bosch, P. Demacker, A. Stalenhoef, 2001, Peritoneal dialysis international : journal of the International Society for Peritoneal Dialysis.

Casus 2 – Antwoord

A. Stalenhoef, J. D. Graaf, 2012 .

The involvement of upstream stimulatory factor 1 in Dutch patients with familial combined hyperlipidemiasâƒž

A. Isaacs, C. Duijn, J. Graaf, 2006 .

Effects of ubiquinone (coenzyme Q10) on myopathy in statin users

A. Stalenhoef, Carel F Schaars, 2008, Current opinion in lipidology.

Decreased adiponectin levels in familial combined hyperlipidemia patients contribute to the atherogenic lipid profile Published, JLR Papers in Press, August 16, 2005. DOI 10.1194/jlr.M500212-JLR200

M. den Heijer, L. V. van Tits, A. Stalenhoef, 2005, Journal of Lipid Research.

A missense mutation Pro157 Arg in lipoprotein lipase (LPLNijmegen) resulting in loss of catalytic activity.

M. Hayden, J. Kastelein, A. Stalenhoef, 1992, European journal of biochemistry.

Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin

M. Hayden, B. Carleton, J. Kastelein, 2011, The Pharmacogenomics Journal.

EFFECTS OF INHIBITION OF CHOLESTEROL SYNTHESIS BY SIMVASTATIN ON THE PRODUCTION OF ADRENOCORTICAL STEROID HORMONES AND ACTH

P. Demacker, A. Stalenhoef, A. Hermus, 1989, Clinical endocrinology.

Abstracts of papers

J. Lammers, H. Petri, M. Danhof, 1966, Journal of Symbolic Logic.

Prevention Familial hypercholesterolaemia in children and adolescents : gaining decades of life by optimizing detection and treatment

J. Borén, S. Humphries, M. Taskinen, 2015 .

Proportion of oxidized LDL relative to plasma apolipoprotein B does not change during statin therapy in patients with heterozygous familial hypercholesterolemia.

J. Graaf, L. V. van Tits, A. Stalenhoef, 2006, Atherosclerosis.

Management of mixed hyperlipidaemia.

A. Stalenhoef, 2005, European heart journal.

Relationship between stearoyl-CoA desaturase activity and plasma triglycerides in human and mouse hypertriglyceridemia Published, JLR Papers in Press, August 16, 2002. DOI 10.1194/jlr.M200189-JLR200

A. Brownlie, R. Krauss, M. Hayden, 2002, Journal of Lipid Research.

Oxidative Stress in Patients with End-Stage Renal Disease prior to the Start of Renal Replacement Therapy

J. van der Palen, L. V. van Tits, A. Stalenhoef, 2004, Nephron Clinical Practice.

Effect of atorvastatin (80 mg) and simvastatin (40 mg) on plasma fibrinogen levels and on carotid intima media thickness in patients with familial hypercholesterolemia.

M. Trip, J. Kastelein, A. Stalenhoef, 2003, The American journal of cardiology.

Differential hs-CRP reduction in patients with familial hypercholesterolemia treated with aggressive or conventional statin therapy.

M. Trip, J. Kastelein, A. Stalenhoef, 2002, Atherosclerosis.

Letter regarding article by Tsimikas et al, "high-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial".

L. V. van Tits, A. Stalenhoef, J. de Graaf, 2005, Circulation.

Long-term safety and efficacy of high-dose atorvastatin treatment in patients with familial hypercholesterolemia.

M. Trip, J. Kastelein, A. Stalenhoef, 2005, The American journal of cardiology.

Paraoxonase-1 and linoleic acid oxidation in familial hypercholesterolemia.

L. V. van Tits, A. Stalenhoef, J. de Graaf, 2005, Biochemical and biophysical research communications.

Endothelial function in familial combined hyperlipidaemia

S. Holewijn, L. V. van Tits, A. Stalenhoef, 2007, European journal of clinical investigation.

The expression of type III hyperlipoproteinemia: involvement of lipolysis genes

C. Duijn, J. Kastelein, R. Frants, 2009, European Journal of Human Genetics.

Plasma annexin A5 level relates inversely to the severity of coronary stenosis.

D. Grobbee, L. V. van Tits, A. Stalenhoef, 2007, Biochemical and biophysical research communications.

Circulating Leptin and Adiponectin Concentrations During Tumor Necrosis Factor Blockade in Patients with Active Rheumatoid Arthritis

M. Netea, P. V. van Riel, F. V. D. van den Hoogen, 2009, The Journal of Rheumatology.

N‐acetylcysteine and serum concentrations of lipoprotein(a)

P. Demacker, A. Stalenhoef, A. Kroon, 1991, Journal of internal medicine.

Phospholipids Present in Oxidized Low-Density Lipoprotein C-Reactive Protein and Annexin A5 Bind to Distinct Sites of Negatively Charged

J. Graaf, L. V. Tits, A. Stalenhoef, 2017 .

C-Reactive Protein and Annexin A5 Bind to Distinct Sites of Negatively Charged Phospholipids Present in Oxidized Low-Density Lipoprotein

L. V. van Tits, A. Stalenhoef, W. V. van Heerde, 2005, Arteriosclerosis, thrombosis, and vascular biology.

C-Reactive Protein and Annexin A 5 Bind to Distinct Sites of Negatively Charged Phospholipids Present in Oxidized Low-Density Lipoprotein

J. Graaf, L. V. Tits, A. Stalenhoef, 2005 .

Hyperglycemia Activates Caspase-1 and TXNIP-Mediated IL-1β Transcription in Human Adipose Tissue

L. Joosten, M. Netea, C. Tack, 2011, Diabetes.

Adiponectin multimer distribution in patients with familial combined hyperlipidemia.

M. den Heijer, S. Holewijn, L. V. van Tits, 2008, Biochemical and biophysical research communications.

Elevated leptin levels in subjects with familial combined hyperlipidemia are associated with the increased risk for CVD.

M. den Heijer, L. V. van Tits, A. Stalenhoef, 2005, Atherosclerosis.

HIGH-DENSITY-LIPOPROTEIN AND MATURITY-ONSET DIABETES

P. Demacker, A. Stalenhoef, J. Lutterman, 1978, The Lancet.

Increased interleukin-1alpha and interleukin-1beta production by macrophages of low-density lipoprotein receptor knock-out mice stimulated with lipopolysaccharide is CD11c/CD18-receptor mediated.

M. Netea, B. Kullberg, J. V. D. van der Meer, 1998, Immunology.

Overexpression of Angiopoietin-Like Protein 4 Protects Against Atherosclerosis Development

A. de Roos, N. Tan, S. Kersten, 2013, Arteriosclerosis, thrombosis, and vascular biology.

Pioglitazone treatment enlarges subcutaneous adipocytes in insulin-resistant patients.

J. A. van der Laak, F. Sweep, C. Tack, 2009, The Journal of clinical endocrinology and metabolism.

Failure of N-acetylcysteine to reduce low-density lipoprotein oxidizability in healthy subjects

P. Demacker, A. Stalenhoef, H. Kleinveld, 2005, European Journal of Clinical Pharmacology.

Decreased in vitro oxidizability of low‐density lipoprotein in hypercholesterolaemic patients treated with 3‐hydroxy‐3‐methyIgIutaryl‐CoA reductase inhibitors

P. Demacker, A. Stalenhoef, H. Kleinveld, 1993, European journal of clinical investigation.

Increased removal of remnants of triglyceride‐rich lipoproteins on a diet rich in polyunsaturated fatty acids

M. B. Katan, M. Katan, P. Demacker, 1991, European journal of clinical investigation.

Response to Howard and Howard

C. Tack, P. Demacker, A. Stalenhoef, 1998, Diabetes Care.

The effects of cyclosporine and prednisone on serum lipid and (apo)lipoprotein levels in renal transplant recipients.

A. Hoitsma, P. Demacker, A. Stalenhoef, 1995, Journal of the American Society of Nephrology : JASN.

Plasma levels of lipid and cholesterol oxidation products and in diabetes mellitus and cigarette smoking : of vitamin treatment

P. Demacker, A. Stalenhoef, M. Mol, 2017 .

The rebound of lipoproteins after LDL-apheresis. Effects on chemical composition and LDL-oxidizability.

P. Demacker, A. Stalenhoef, A. Kroon, 1999, Atherosclerosis.

Plasma levels of lipid and cholesterol oxidation products and cytokines in diabetes mellitus and cigarette smoking: effects of vitamin E treatment.

P. Demacker, A. Stalenhoef, M. Mol, 1997, Atherosclerosis.

Decreased resistance against in vitro oxidation of LDL from patients with familial defective apolipoprotein B-100.

J. Kastelein, P. Demacker, A. Stalenhoef, 1994, Arteriosclerosis and thrombosis : a journal of vascular biology.

Indications for the presence of circulating peroxidized low density lipoproteins in WHHL rabbits treated with antioxidants.

P. Demacker, A. Stalenhoef, A. Hijmans, 1993, Atherosclerosis.

Differences in the low density lipoprotein subfraction profile between oral contraceptive users and controls.

D. Swinkels, J. Graaf, P. Demacker, 1993, The Journal of clinical endocrinology and metabolism.

In vivo oxidised cholesterol in atherosclerosis.

M. Katan, P. Demacker, A. Stalenhoef, 1993, Atherosclerosis.

Expression of Type III Hyperlipoproteinemia in Apolipoprotein E2 (Arg158→Cys) Homozygotes Is Associated With Hyperinsulinemia

C. V. van Duijn, J. Kastelein, L. Havekes, 2002, Arteriosclerosis, thrombosis, and vascular biology.

Reducing cardiac after-load by lowering blood viscosity in patients with familial hypercholesterolemia – A pilot study. Possible mechanism for occurrence of anemia in chronic heart failure patients?

A. Stalenhoef, G. Pop, M. Boer, 2016 .

Fatty Acid Composition and Vitamin E Content of Experimental Diets Component Study Diet Oleic Linoleic Oleic

P. Demacker, A. Stalenhoef, N. J. Fouw, 2017 .

Ultracentrifugation in swinging-bucket and fixed-angle rotors evaluated for isolation and determination of high-density lipoprotein subfractions HDL2 and HDL3.

P. Demacker, A. Stalenhoef, A. van't Laar, 1983, Clinical chemistry.

Ultracentrifugationin Swinging-Bucketand Fixed-AngleRotors Evaluatedfor Isolationand Determinationof High-DensityLipoproteinSubfractionsHDL2 and HDL3

P. Demacker, A. Stalenhoef, P. Stuyt, 1983 .

Lipoprotein (a) concentrations in patients with familial combined hyperlipidemia and hypertension.

M. Netea, P. Demacker, A. Stalenhoef, 1999, The Netherlands journal of medicine.

Chylomicrons in disease: a renaissance in lipidology International Symposium of Chylomicrons in Disease (ISCD), Lake Louise, Alberta, Canada, March 6th-8th, 2008.

G. Watts, A. Stalenhoef, 2008, Atherosclerosis. Supplements.

Cardiac complication after experimental human malaria infection: a case report

R. Sauerwein, A. Stalenhoef, Q. de Mast, 2009, Malaria Journal.

On the presumed inaccuracy of the Friedewald formula in hypertriglyceridemic plasma: a role for imprecise analysis?

P. Demacker, A. Stalenhoef, H. Willems, 1996, Clinical chemistry.

Red wine consumption does not affect oxidizability of low-density lipoproteins in volunteers.

M. Katan, P. Demacker, A. Stalenhoef, 1996, The American journal of clinical nutrition.

Increased Removal of / 8-Very Low Density Lipoproteins After Ethinyl Estradiol Is Associated With Increased mRNA Levels for Hepatic Lipase , Lipoprotein Lipase , and the Low Density Lipoprotein Receptor in Watanabe Heritable Hyperlipidemic Rabbits

J. Auwerx, P. Demacker, A. Stalenhoef, 2005 .

Beta-VLDL accumulation in familial dysbetalipoproteinemia is associated with increased exchange or diffusion of chylomicron lipids to apo B-100 containing triglyceride-rich lipoproteins.

P. Demacker, A. Stalenhoef, S. Bredie, 1998, Atherosclerosis.

A comparative study of the effects of acipimox and clofibrate in type III and type IV hyperlipoproteinemia.

P. Demacker, A. Stalenhoef, P. Stuyt, 1985, Atherosclerosis.

Role of Insulin Resistance in Familial Combined Hyperlipidemia

A. Stalenhoef, J. de Graaf, M. Veerkamp, 2005, Arteriosclerosis, thrombosis, and vascular biology.

Cholesterol-raising factor from boiled coffee does not pass a paper filter.

M. Katan, P. Demacker, A. Stalenhoef, 1991, Arteriosclerosis and thrombosis : a journal of vascular biology.

Effect of aging and obesity on the expression of dyslipidaemia in children from families with familial combined hyperlipidaemia.

A. Stalenhoef, S. Bredie, J. de Graaf, 2007, Clinical science.

Th-P15:240 The effect of ageing and obesity on the expression of dyslipidemia in children from FCH families

J. Graaf, A. Stalenhoef, S. Bredie, 2006 .

Paraoxonase (PON1) is associated with familial combined hyperlipidemia.

L. V. van Tits, A. Stalenhoef, J. de Graaf, 2008, Atherosclerosis.

Chylomicron processing in familial dysbetalipoproteinemia and familial combined hyperlipidemia studied with vitamin A and E as markers: a new physiological concept.

P. Demacker, A. Stalenhoef, M. Hectors, 2000, Atherosclerosis.

Effects of Partial Ileal Bypass Surgery on Low-Density Lipoprotein Metabolism in Watanabe Heritable Hyperlipidemic Rabbits

A. Stalenhoef, M. Mol, 1987 .

The prevalence of peripheral vascular disease in familial hypercholesterolaemia

A. Stalenhoef, A. Kroon, A. Stalenhoef, 1995, Journal of internal medicine.

Simvastatin (MK-733): a potent cholesterol synthesis inhibitor in heterozygous familial hypercholesterolaemia.

J. Schouten, A. Stalenhoef, D. Erkelens, 1988, Atherosclerosis.

Apo E polymorphism and the removal of remnants of triglyceride-rich lipoproteins in normolipidemic subjects during a carbohydrate-rich diet.

P. Demacker, A. Stalenhoef, A. van't Laar, 1989, Clinical nutrition.

Pregnancy in a patient with homozygous familial hypercholesterolemia treated with long-term low-density lipoprotein apheresis.

D. Swinkels, A. Stalenhoef, A. Kroon, 1994, Metabolism: clinical and experimental.

Metabolic pathogenesis of familial combined hyperlipidaemia with emphasis on insulin resistance, adipose tissue metabolism and free fatty acids.

A. Stalenhoef, J. de Graaf, M. Veerkamp, 2002, Journal of the Royal Society of Medicine.

Efficacy and tolerability of simvastatin (MK-733).

A. Stalenhoef, M. Mol, P. Stuyt, 1989, The American journal of medicine.

[The practice guideline 'Diagnosis and treatment of familial hypercholesterolaemia' of the Dutch Health Care Insurance Board].

J. Jukema, J. Kastelein, F. Visseren, 2006, Nederlands tijdschrift voor geneeskunde.

Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in normal and lipoprotein lipase-deficient humans.

R. Havel, M. Malloy, J. Kane, 1984, Proceedings of the National Academy of Sciences of the United States of America.

Diagnostic criteria in relation to the pathogenesis of familial combined hyperlipidemia.

A. Stalenhoef, J. de Graaf, G. M. van der Vleuten, 2004, Seminars in vascular medicine.

Both inherited susceptibility and environmental exposure determine the low-density lipoprotein-subfraction pattern distribution in healthy Dutch families.

D. Swinkels, J. Graaf, P. Demacker, 1992, American journal of human genetics.

Lipoprotein(a) Inhibits Lipopolysaccharide-Induced Tumor Necrosis Factor Alpha Production by Human Mononuclear Cells

L. Jacobs, M. Netea, B. Kullberg, 1998, Infection and Immunity.

The dense low-density lipoprotein (LDL) subfractions are more potent than buoyant LDL for binding and neutralization of lipopolysaccharide

L. Jacobs, M. Netea, J. V. D. van der Meer, 1997 .

The LDL-apheresis atherosclerosis regression study (Laars)

A. Stalenhoef, A. Kroon, W. Aengevaeren, 1992 .

Low-density lipoprotein catabolism in WHHL rabbits after partial ileal bypass surgery.

P. Demacker, A. Stalenhoef, A. van't Laar, 1989, Biochimica et biophysica acta.

The effect of the initiation of renal replacement therapy on lipid profile and oxidative stress during the first 6 months of treatment.

J. van der Palen, A. Stalenhoef, B. Dikkeschei, 2005, Clinica chimica acta; international journal of clinical chemistry.

Metabolism of apolipoproteins B-48 and B-100 of triglyceride-rich lipoproteins in patients with familial dysbetalipoproteinemia.

R. Havel, M. Malloy, J. Kane, 1986, The Journal of clinical investigation.

Low-density lipoprotein turnover in inbred strains of rabbits hypo- or hyperresponsive to dietary cholesterol

G. Meijer, P. Demacker, A. Stalenhoef, 1992, Lipids.

Partial ileal bypass reduces the production rate of low density lipoproteins in Watanabe heritable hyperlipidemic rabbits.

P. Demacker, A. Stalenhoef, A. van 't Laar, 1984, Journal of lipid research.

Pregnancy in women suffering from familial hypercholesterolemia: a harmful period for both mother and newborn?

J. Kastelein, J. V. D. van der Post, A. Stalenhoef, 2009, Current opinion in lipidology.

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease

Catherine Boileau, Päivi Pajukanta, Anne Tybjærg-Hansen, 2013, European heart journal.

The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels.

M. V. van’t Hof, P. Demacker, A. Stalenhoef, 2000, Atherosclerosis.

Morbidity and mortality in first-degree relatives of C282Y homozygous probands with clinically detected haemochromatosis compared with the general population: the HEmochromatosis FAmily Study (HEFAS).

A. Verbeek, D. Swinkels, J. Hendriks, 2007, The Netherlands journal of medicine.

UvA-DARE ( Digital Academic Repository ) Familial hypercholesterolemia in childhood : diagnostics , therapeutical options and risk stratification

A. Stalenhoef, J. Kastelein, M. N. Vissers, 2009 .

Familial hypercholesterolemia in childhood : diagnostics , therapeutical options and risk stratification

A. Stalenhoef, J. Kastelein, M. N. Vissers, 2009 .

A boy with autosomal recessive hypercholesterolaemia.

J. Kastelein, A. Stalenhoef, M. N. Vissers, 2004, The Netherlands journal of medicine.

Nomogram to Diagnose Familial Combined Hyperlipidemia on the Basis of Results of a 5-Year Follow-Up Study

J. Hendriks, P. Demacker, A. Stalenhoef, 2004, Circulation.

Two novel molecular defects in the LCAT gene are associated with fish eye disease.

J. Kastelein, P. Demacker, A. Stalenhoef, 1996, Arteriosclerosis, thrombosis, and vascular biology.

Fingerprick cholesterol testing with the "Reflotron".

C. V. van Herpen, M. Katan, A. Stalenhoef, 1988, Clinical chemistry.

Familial combined hyperlipidemia: from molecular insights to tailored therapy

M. V. van Greevenbroek, A. Stalenhoef, J. de Graaf, 2014, Current opinion in lipidology.

Identification of apolipoprotein E polymorphism by using synthetic oligonucleotides.

H. Ropers, B. Wieringa, A. Stalenhoef, 1988, Journal of lipid research.

Simvastatin Treatment for Inflammatory Attacks of the Hyperimmunoglobulinemia D and Periodic Fever Syndrome

J. Meer, J. Drenth, A. Stalenhoef, 2004, Clinical pharmacology and therapeutics.

Fatty acids engagement with TLR2 drive IL-1 β production via ASC-caspase-1 pathway by urate crystals in gouty arthritis

M. Oosting, L. Joosten, M. Netea, 2011 .

Chlamydia pneumoniae stimulates IFN-gamma synthesis through MyD88-dependent, TLR2- and TLR4-independent induction of IL-18 release.

L. Jacobs, M. Netea, J. Galama, 2004, Journal of immunology.

5-Year Follow-Up Study Nomogram to Diagnose Familial Combined Hyperlipidemia on the Basis of Results of a

J. Hendriks, J. Graaf, P. Demacker, 2017 .

Genetic heterogeneity in familial dysbetalipoproteinemia. The E2(lys146----gln) variant results in a dominant mode of inheritance.

P. de Knijff, R. Frants, L. Havekes, 1990, Journal of lipid research.

Chylomicron apolipoprotein B catabolism

A. Stalenhoef, 1984, Diabetologia.

Apolipoprotein-E-deficient mice exhibit an increased susceptibility to disseminated candidiasis.

M. Netea, B. Kullberg, J. V. D. van der Meer, 2004, Medical mycology.

Casus 38 – Antwoord

A. Stalenhoef, J. D. Graaf, 2012 .

LPS-induced cytokine production and expression of beta2-integrins and CD14 by peripheral blood mononuclear cells of patients with homozygous familial hypercholesterolemia.

M. Netea, B. Kullberg, J. V. D. van der Meer, 1998, Atherosclerosis.

Effects of ketoconazole on plasma lipids and lipoprotein(a) in familial hypercholesterolaemia, compared with simvastatin.

A. Stalenhoef, J. de Graaf, P. Stuyt, 1997, The Netherlands journal of medicine.

Studies on the function of hepatic lipase in the cat after immunological blockade of the enzyme in vivo.

P. Demacker, A. Stalenhoef, A. Hijmans, 1988, Atherosclerosis.

A study of the lipid transport system in the cat, Felix domesticus.

P. Demacker, A. Stalenhoef, H. Hak-Lemmers, 1987, Atherosclerosis.

Combined deficiency of apolipoprotein C-II and lipoprotein lipase in familial hyperchylomicronemia.

P. Demacker, A. Stalenhoef, A. Casparie, 1981, Metabolism: clinical and experimental.

Casus 15 – Antwoord

A. Stalenhoef, J. D. Graaf, 2012 .

The Asp299Gly Toll-like receptor 4 polymorphism in advanced aortic atherosclerosis.

M. Netea, T. Leiner, A. Kroon, 2007, The Netherlands journal of medicine.

Raised serum levels of soluble CD40 ligand in patients with familial hypercholesterolemia: downregulatory effect of statin therapy.

J. Kastelein, S. Frøland, T. Ueland, 2003, Journal of the American College of Cardiology.

Effect of troglitazone on lipoprotein(a) levels in obese subjects.

C. Tack, P. Demacker, A. Stalenhoef, 1999, Diabetes care.

The lipoprotein lipase (ASN291→SER) mutation is associated with elevated lipid levels in familial combined hyperlipidemia

D. Boomsma, L. Sandkuyl, J. Kastelein, 1995 .

Casus 36 – Antwoord

A. Stalenhoef, J. D. Graaf, 2012 .

Phytosterol consumption and the anabolic steroid boldenone in humans: A hypothesis piloted

A. Stalenhoef, M. Ros, H. Verhagen, 2007, Food additives and contaminants.

Effect of plant sterol‐enriched margarine on plasma lipids and sterols in subjects heterozygous for phytosterolaemia

P. Demacker, A. Stalenhoef, M. Hectors, 2001, Journal of internal medicine.

Neutrophil superoxide-anion generating capacity in chronic smoking: Effect of long-term α-tocopherol therapy

J. Graaf, P. Demacker, A. Stalenhoef, 2003, Journal of Biosciences.

Serum non-transferrin-bound iron and low-density lipoprotein oxidation in heterozygous hemochromatosis.

D. Swinkels, L. V. van Tits, A. Stalenhoef, 2006, Biochemical and biophysical research communications.

Low-density lipoprotein receptor-deficient mice are protected against lethal endotoxemia and severe gram-negative infections.

M. Netea, J. Meer, B. Kullberg, 1996, The Journal of clinical investigation.

Apolipoprotein C in Type 2 (non-insulin-dependent) diabetic patients with hypertriglyceridaemia

P. Demacker, A. Stalenhoef, J. Lutterman, 1982, Diabetologia.

Chondrosarcoma coexistent with dermatomyositis.

A. Stalenhoef, M. Mol, A. Boerbooms, 1986, Arthritis and rheumatism.

Autoantibodies against oxidized low-density lipoprotein and lipid profile in patients with chronic periaortitis: case–control study

A. Stalenhoef, E. Berg, L. J. Tits, 2011, Rheumatology International.

Oxidation of low-density lipoproteins by acellular components of Chlamydia pneumoniae.

L. Jacobs, M. Netea, C. Dinarello, 2000, The Journal of infectious diseases.

Oxidized low-density lipoprotein is not equal to oxidative stress.

L. V. van Tits, A. Stalenhoef, 2008, The American journal of cardiology.

Paraoxonase (PON1) and the risk for coronary heart disease and myocardial infarction in a general population of Dutch women.

P. Peeters, Y. T. van der Schouw, L. V. van Tits, 2008, Atherosclerosis.

Fat loading experiments with the vitamins A and E suggest that in postprandial lipemia transfer/diffusion of chylomicron lipids to VLDL contributes to beta-VLDL formation.

P. Demacker, A. Stalenhoef, S. Bredie, 1998, Atherosclerosis.

Hypo‐ and Hyperresponse of Serum Cholesterol Level and Low Density Lipoprotein Production and Degradation to Dietary Cholesterol in Man a

A. Stalenhoef, J. Glatz, P. Turner, 1993, Annals of the New York Academy of Sciences.

Bacterial lipopolysaccharide binds and stimulates cytokine-producing cells before neutralization by endogenous lipoproteins can occur.

L. Jacobs, M. Netea, B. Kullberg, 1998, Cytokine.

W16-P-087 Effects of rosuvastatin on insulin sensitivity in patients with familial combined hyperlipidemia (FCH)

C. Tack, J. Graaf, A. Stalenhoef, 2005 .

Apolipoprotein E*3-Leiden allele results from a partial gene duplication in exon 4.

P. de Knijff, R. Frants, L. Havekes, 1989, Biochemical and biophysical research communications.

High plasma level of remnant-like particles cholesterol in familial combined hyperlipidemia.

A. Stalenhoef, J. de Graaf, G. Dallinga-Thie, 2007, The Journal of clinical endocrinology and metabolism.

Efficacy and Safety of a Novel Cholesteryl Ester Transfer Protein Inhibitor, JTT-705, in Humans: A Randomized Phase II Dose-Response Study

A. Zwinderman, J. Kastelein, A. Stalenhoef, 2002, Circulation.

Plasma activities of lecithin:cholesterol acyltransferase, lipid transfer proteins and post-heparin lipases in inbred strains of rabbits hypo- or hyper-responsive to dietary cholesterol.

G. Meijer, P. Demacker, A. Stalenhoef, 1993, The Biochemical journal.

ACE inhibitors and LDL-apheresis with dextran sulphate adsorption

A. Stalenhoef, A. Kroon, M. Mol, 1992, The Lancet.

Homozygous familial hypercholesterolaemia: metabolic studies and treatment with LDL apheresis.

A. Stalenhoef, M. Mol, 1990, The Netherlands journal of medicine.

Casus 9 – Antwoord

A. Stalenhoef, J. D. Graaf, 2012 .

The case for case reports in the Netherlands Journal of Medicine.

J. Drenth, A. Stalenhoef, P. Smits, 2006, The Netherlands journal of medicine.

Adrenocortical function in patients on simvastatin

A. Stalenhoef, M. Mol, 1990, The Lancet.

Interaction Between Genes and Environment in Inherited Lipid Disorders Determines Clinical Presentation

A. Stalenhoef, 2002, Cardiovascular Drugs and Therapy.

Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis.

F. Gabreëls, F. Barkhof, B. Engelen, 1999, Metabolism: clinical and experimental.

Treatment of primary hypercholesterolaemia. Short‐term efficacy and safety of increasing doses of simvastatin and pravastatin: a double‐blind comparative study

J. Kastelein, A. Stalenhoef, A. Kroon, 1993, Journal of internal medicine.

Engagement of fatty acids with Toll-like receptor 2 drives interleukin-1β production via the ASC/caspase 1 pathway in monosodium urate monohydrate crystal-induced gouty arthritis.

M. Oosting, L. Joosten, M. Netea, 2010, Arthritis and rheumatism.

The effect of cholesterol reduction on the endothelial function and progression of atherosclerosis in WHHL rabbits.

P. D. de Wilde, H. Buikema, P. Demacker, 1993, Atherosclerosis.

Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis

M. Netea, M. Heijer, P. V. van Riel, 2007, Annals of the rheumatic diseases.

Increased hepatic lipase activity and increased direct removal of very-low-density lipoprotein remnants in Watanabe heritable hyperlipidaemic (WHHL) rabbits treated with ethinyl oestradiol.

P. Demacker, A. Stalenhoef, M. Mol, 1990, The Biochemical journal.

Review the Polygenic Nature of Hypertriglyceridaemia: Implications for Defi Nition, Diagnosis, and Management

J. Borén, S. Humphries, M. Taskinen, 2022 .

Two genes that map to the STSL locus cause sitosterolemia: genomic structure and spectrum of mutations involving sterolin-1 and sterolin-2, encoded by ABCG5 and ABCG8, respectively.

A. Pandya, A. Brooks-Wilson, H. Brewer, 2001, American journal of human genetics.

Fine mapping of a gene responsible for regulating dietary cholesterol absorption; founder effects underlie cases of phytosterolaemia in multiple communities

Jurg Ott, Derek Gordon, Hideki Hidaka, 2001, European Journal of Human Genetics.

Mapping a gene involved in regulating dietary cholesterol absorption. The sitosterolemia locus is found at chromosome 2p21.

M. Polymeropoulos, S. Grundy, M. Brownstein, 1998, The Journal of clinical investigation.

The Metabolic Syndrome: Targeting Dyslipidaemia to Reduce Coronary Risk

A. Stalenhoef, H. Ginsberg, Henry N Ginsberg, 2003, Journal of cardiovascular risk.

The genetics of familial combined hyperlipidaemia

C. Stehouwer, J. Graaf, A. Stalenhoef, 2012, Nature Reviews Endocrinology.

Effects of alpha-tocopherol on superoxide production and plasma intercellular adhesion molecule-1 and antibodies to oxidized LDL in chronic smokers.

L. V. van Tits, P. Demacker, A. Stalenhoef, 2001, Free radical biology & medicine.

Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline.

F. Sacks, M. Murad, A. Goldberg, 2012, The Journal of clinical endocrinology and metabolism.

Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial.

M. Eriksson, J. Kastelein, M. Trip, 2010, Clinical therapeutics.

Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL

A. Stalenhoef, J. de Graaf, 2008, Current opinion in lipidology.

Simvastatin with or without ezetimibe in familial hypercholesterolemia.

A. Zwinderman, D. Gaudet, J. Kastelein, 2008, The New England journal of medicine.

Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty‐person/ten‐country panel

R. Krauss, S. Humphries, C. Furberg, 2006, Journal of internal medicine.

The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk.

M. Netea, P. V. van Riel, J. V. D. van der Meer, 2007, Journal of lipid research.

Circulating Lipoproteins Are a Crucial Component of Host Defense against Invasive Salmonella typhimurium Infection

L. Joosten, M. Netea, B. Kullberg, 2009, PloS one.

Non‐LPS components of Chlamydia pneumoniae stimulate cytokine production through Toll‐like receptor 2‐dependent pathways

M. Netea, J. Galama, C. Dinarello, 2002, European journal of immunology.

Vascular graft infection in aortoiliac and aortofemoral bypass surgery: clinical presentation, diagnostic strategies and results of surgical treatment.

A. Stalenhoef, S. Bredie, P. L. Klemm, 2004, The Netherlands journal of medicine.

What is the role of non-invasive measurements of atherosclerosis in individual cardiovascular risk prediction?

A. Stalenhoef, J. de Graaf, Jacqueline de Graaf, 2007, Clinical science.

Towards a role of interleukin-32 in atherosclerosis.

L. Joosten, M. Netea, C. Dinarello, 2013, Cytokine.

The LDL-Apheresis Atherosclerosis Regression Study (LAARS)(Symposium 7: LDL and Lp(a) Apheresis)

A. Stalenhoef, A. Kroon, T. Werf, 1997 .

The involvement of upstream stimulatory factor 1 in Dutch patients with familial combined hyperlipidemias⃞ Published, JLR Papers in Press, October 25, 2006.

A. Isaacs, C. V. van Duijn, A. Stalenhoef, 2007, Journal of Lipid Research.

A common genetic mechanism determines plasma apolipoprotein B levels and dense LDL subfraction distribution in familial combined hyperlipidemia.

L. Kiemeney, S. Juo, P. Demacker, 1998, American journal of human genetics.

The inflammasome and caspase-1 activation: a new mechanism underlying increased inflammatory activity in human visceral adipose tissue.

L. Joosten, M. Netea, C. Tack, 2011, Endocrinology.

The Netherlands Journal of Medicine's hit list: best cited articles in 2003.

J. Drenth, A. Stalenhoef, P. Smits, 2005, The Netherlands journal of medicine.

alpha-tocopherol supplementation decreases production of superoxide and cytokines by leukocytes ex vivo in both normolipidemic and hypertriglyceridemic individuals.

L. V. van Tits, P. Demacker, A. Stalenhoef, 2000, The American journal of clinical nutrition.

Compromised LCAT Function Is Associated With Increased Atherosclerosis

A. Zwinderman, J. Kastelein, A. Stalenhoef, 2005, Circulation.

Serum triglycerides and risk of cardiovascular disease.

J. Graaf, A. Stalenhoef, J. de Graaf, 2012, Biochimica et biophysica acta.

Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis.

A. Goldberg, I. Goldberg, A. Stalenhoef, 2014, Best practice & research. Clinical endocrinology & metabolism.

Novel drugs in familial combined hyperlipidemia: lessons from type 2 diabetes mellitus

C. Stehouwer, M. V. van Greevenbroek, A. Stalenhoef, 2010, Current opinion in lipidology.

Haplotype analyses of the APOA5 gene in patients with familial combined hyperlipidemia.

P. Talmud, A. Isaacs, C. V. van Duijn, 2007, Biochimica et biophysica acta.

The Gln223Arg polymorphism in the leptin receptor is associated with familial combined hyperlipidemia

H. Blom, L. Kluijtmans, J. Graaf, 2006, International Journal of Obesity.

Familial apolipoprotein CII deficiency: A preliminary analysis of the gene defect in two independent families

S. Humphries, O. Myklebost, R. Williamson, 1984, Human Genetics.

The Molecular Basis of ApoC-II Deficiency

R. Gregg, H. Brewer, A. Stalenhoef, 1989 .

JTT-705: is there still future for a CETP inhibitor after torcetrapib?

A. Stalenhoef, A. Rennings, 2008, Expert opinion on investigational drugs.

A review of CETP and its relation to atherosclerosis Published, JLR Papers in Press, September 1, 2004. DOI 10.1194/jlr.R400007-JLR200

J. Kastelein, E. Stroes, A. Stalenhoef, 2004, Journal of Lipid Research.

Cholesterol in end-stage renal disease: the good, the bad or the ugly?

J. Wetzels, L. V. van Tits, A. Stalenhoef, 2008, The Netherlands journal of medicine.

Indications for a contribution of paraoxonase type-1 to plasma high density lipoprotein levels in patients with familial hypercholesterolemia

J. Kastelein, J. Graaf, A. Stalenhoef, 2004 .

The lipoprotein lipase (Asn291-->Ser) mutation is associated with elevated lipid levels in families with familial combined hyperlipidaemia.

P. de Knijff, D. Boomsma, J. Kastelein, 1996, Atherosclerosis.

Serum carotenoids, alpha-tocopherol and mortality risk in a prospective study among Dutch elderly.

E. Schouten, F. Kok, A. Stalenhoef, 2001, International journal of epidemiology.

TLR4 polymorphisms, infectious diseases, and evolutionary pressure during migration of modern humans

M. Netea, O. Doumbo, H. Brunner, 2007, Proceedings of the National Academy of Sciences.

Casus 40 – Antwoord

A. Stalenhoef, J. D. Graaf, 2012 .

LDL-cholesterol lowering and atherosclerosis--clinical benefit and possible mechanisms: an update.

A. Stalenhoef, A. Kroon, A. Stalenhoef, 1997, The Netherlands journal of medicine.

Effect of Apheresis of Low-Density Lipoprotein on Peripheral Vascular Disease in Hypercholesterolemic Patients with Coronary Artery Disease

A. Stalenhoef, A. Kroon, W. van Asten, 1996, Annals of Internal Medicine.

Severity of iron overload of proband determines serum ferritin levels in families with HFE-related hemochromatosis: the HEmochromatosis FAmily Study.

A. Verbeek, D. Swinkels, J. Hendriks, 2009, Journal of hepatology.

A comparative study with rosuvastatin in subjects with metabolic syndrome: results of the COMETS study.

S. Tonstad, C. Ballantyne, C. Sarti, 2005, European heart journal.

Human lipoproteins have divergent neutralizing effects on E. coli LPS, N. meningitidis LPS, and complete Gram-negative bacteria Published, JLR Papers in Press, February 1, 2004. DOI 10.1194/jlr.M300453-JLR200

L. Jacobs, M. Netea, J. V. D. van der Meer, 2004, Journal of Lipid Research.

Familial combined hyperlipidemia is associated with alterations in the cholesterol synthesis pathway.

E. Schaefer, L. V. van Tits, A. Stalenhoef, 2010, Arteriosclerosis, thrombosis, and vascular biology.

Variable expression of familial dysbetalipoproteinemia in apolipoprotein E*2 (Lys146-->Gln) Allele carriers.

P. de Knijff, D. Boomsma, J. Kastelein, 1994, The Journal of clinical investigation.

Paraoxonase Genotype, LDL-oxidation and Carotid Atherosclerosis in Male Life-long Smokers

L. V. van Tits, A. Stalenhoef, J. de Graaf, 2004, Free radical research.

Non-invasive measurements of atherosclerosis (NIMA): current evidence and future perspectives.

M. den Heijer, S. Holewijn, A. Stalenhoef, 2010, The Netherlands journal of medicine.

Variation in non-invasive measurements of vascular function in healthy volunteers during daytime.

S. Holewijn, A. Stalenhoef, J. de Graaf, 2005, Clinical science.

Familial chylomicronemia caused by a novel type of mutation in the APOE-CI-CIV-CII gene cluster encompassing both the APOCII gene and the first APOCIV gene mutation: APOCII-CIV(Nijmegen).

R. Frants, A. Stalenhoef, J. de Graaf, 2000, Biochemical and biophysical research communications.

Type III hyperlipoproteinaemia: the turnover rate of plasma triglycerides and the response to clofibrate.

P. Demacker, A. Stalenhoef, J. Lutterman, 1982, The Netherlands journal of medicine.

Acellular components of Chlamydia pneumoniae stimulate cytokine production in human blood mononuclear cells

M. Netea, J. Galama, C. Dinarello, 2000, European journal of immunology.

Non-transferrin-bound iron is associated with plasma level of soluble intercellular adhesion molecule-1 but not with in vivo low-density lipoprotein oxidation.

D. Swinkels, J. Graaf, L. V. van Tits, 2007, Atherosclerosis.

Should preclinical vascular abnormalities be measured in asymptomatic adults to improve cardiovascular risk stratification?

S. Holewijn, A. Stalenhoef, J. de Graaf, 2011, Current opinion in lipidology.

A Comparison of Simvastatin and Atorvastatin up to Maximal Recommended Doses in a Large Multicenter Randomized Clinical Trial

M. Mercuri, D. Hunninghake, D. Illingworth, 2001 .

Rationale, Design and Baseline Characteristics of a Clinical Trial Comparing the Effects of Robust vs Conventional Cholesterol Lowering and Intima Media Thickness in Patients with Familial Hypercholesterolaemia

M. Trip, J. Kastelein, H. Wollersheim, 2000, Clinical drug investigation.

LPS-induced release of IL-1 beta, IL-1Ra, IL-6, and TNF-alpha in whole blood from patients with familial hypercholesterolemia: no effect of cholesterol-lowering treatment.

M. Netea, J. V. D. van der Meer, P. Demacker, 2006, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

Increased Levels of Low-Density Lipoprotein Oxidation in Patients with Familial Hypercholesterolemia and in End-Stage Renal Disease Patients on Hemodialysis

J. Graaf, L. V. Tits, P. Demacker, 2003, Laboratory Investigation.

Effect of glutathione S-transferase M1 genotype on progression of atherosclerosis in lifelong male smokers.

H. Wollersheim, F. Kok, A. Stalenhoef, 2001, Atherosclerosis.

Statins are less effective in common daily practice among patients with hypercholesterolemia: the REALITY-PHARMO study;

R. Herings, O. Klungel, A. Stalenhoef, 2004, Current medical research and opinion.

Th e CETP inhibitor Torcetrapib and Off -target Toxicity A Pooled Analysis of the RADIANCE Trials.

D. Grobbee, M. Bots, G. Evans, 2008 .

Apolipoprotein CII (apo CII) gene expression defect in an individual with familial apo CII deficiency.

S. Humphries, A. Stalenhoef, P. Davison, 1987, Biochemical and biophysical research communications.

The V73M mutation in the hepatic lipase gene is associated with elevated cholesterol levels in four Dutch pedigrees with familial combined hyperlipidemia.

H. Snieder, J. Kastelein, R. Frants, 2000, Atherosclerosis.

The V 73 M mutation in the hepatic lipase gene is associated with elevated cholesterol levels in four Dutch pedigrees with familial combined hyperlipidemia

H. Snieder, J. Kastelein, R. Frants, 2000 .

H. Snieder, D. Boomsma, J. Kastelein, 1998, Atherosclerosis.

Circulating CXCL16 is not related to circulating oxLDL in patients with rheumatoid arthritis.

P. V. van Riel, G. Adema, T. Radstake, 2007, Biochemical and biophysical research communications.

Segregation analysis of plasma apolipoprotein B levels in familial combined hyperlipidemia.

L. Kiemeney, P. Demacker, A. Stalenhoef, 1997, Arteriosclerosis, thrombosis, and vascular biology.

A deletion mutation in the ApoC-II gene (ApoC-II Nijmegen) of a patient with a deficiency of apolipoprotein C-II.

R. Gregg, H. Brewer, A. Stalenhoef, 1988, The Journal of biological chemistry.

Molecular genetics of apoC-II and lipoprotein lipase deficiency.

H. Brewer, A. Stalenhoef, J. Brunzell, 1991, Advances in experimental medicine and biology.

Troglitazone Decreases the Proportion of Small, Dense LDL and Increases the Resistance of LDL to Oxidation in Obese Subjects

C. Tack, P. Demacker, A. Stalenhoef, 1998, Diabetes Care.

Native LDL potentiate TNF alpha and IL-8 production by human mononuclear cells.

L. Jacobs, M. Netea, B. Kullberg, 2002, Journal of lipid research.

W M Wiersinga, T Diekman, P N Demacker, 2022 .

Combining risk markers improves cardiovascular risk prediction in women.

L. Kiemeney, M. den Heijer, S. Holewijn, 2014, Clinical science.

Pulse wave velocity in familial combined hyperlipidemia.

S. Holewijn, L. V. van Tits, A. Stalenhoef, 2007, American journal of hypertension.

Plasma homocysteine in subjects with familial combined hyperlipidemia.

H. Blom, M. den Heijer, A. Stalenhoef, 2003, Atherosclerosis.

Increased removal of beta-very low density lipoproteins after ethinyl estradiol is associated with increased mRNA levels for hepatic lipase, lipoprotein lipase, and the low density lipoprotein receptor in Watanabe heritable hyperlipidemic rabbits.

J. Auwerx, P. Demacker, A. Stalenhoef, 1991, Arteriosclerosis and Thrombosis A Journal of Vascular Biology.

[Cardiovascular prevention in the over-80 age group is beneficial].

A. Stalenhoef, 2008, Nederlands tijdschrift voor geneeskunde.

The role of modification of lipoproteins and of the immune system in early atherogenesis.

P. Demacker, A. Stalenhoef, M. Mol, 1993, The Netherlands journal of medicine.

LDL-C reductions and goal attainment among naive statin users in the Netherlands: real life results*

R. Herings, A. Stalenhoef, J. O'donnell, 2008, Current medical research and opinion.

The significance of femoral intima-media thickness and plaque scoring in the Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP) study

J. Kastelein, A. Stalenhoef, T. Smilde, 2003, European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology.

A comparison of simvastatin and atorvastatin up to maximal recommended doses in a large multicenter randomized clinical trial.

M. Mercuri, D. Hunninghake, D. Illingworth, 2001, Current medical research and opinion.

Obstructive jaundice in von Recklinghausen’s disease • Histoplasma capsulatum in chronic lymphocytic leukaemia . Exposure to calcium and phosphate in kidney disease Euthyroid enlargement of the thyroid gland: what is your diagnosis?

C. A. Groot, M. Heijer, P. Speelman, 2010 .

The metabolic syndrome and its traits as risk factors for subclinical atherosclerosis.

D. Swinkels, M. den Heijer, S. Holewijn, 2009, The Journal of clinical endocrinology and metabolism.

HYPERLIPOPROTEINAEMIA TYPE V AND APOLIPOPROTEIN E4

P. Demacker, A. Stalenhoef, P. Stuyt, 1982, The Lancet.

Pancreatitis induced by oestrogen in a patient with type I hyperlipoproteinaemia.

P. Demacker, A. Stalenhoef, P. Stuyt, 1986, British medical journal.

Absence of glomerulosclerosis in Watanabe heritable hyperlipidemic rabbits.

P. Westenend, A. Stalenhoef, A. Kroon, 1993, Nephron.

Effects of Atorvastatin and Simvastatin on Low-Density Lipoprotein Subtraction Profile, Low-Density Lipoprotein Oxidizability, and Antibodies to Oxidized Low-Density Lipoprotein in Relation to Carotid Intima Media Thickness in Familial Hypercholesterolemia

J. Kastelein, L. V. van Tits, A. Stalenhoef, 2004, Journal of Investigative Medicine.

Running on age in a 15-km road run: minor influence of age on performance

M. Hopman, A. Stalenhoef, M. Rikkert, 2010, European Review of Aging and Physical Activity.

Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study

R. Herings, S. Johansson, A. Stalenhoef, 2009, Current medical research and opinion.

Oxidized low-density lipoprotein induces calcium influx in polymorphonuclear leukocytes.

L. V. van Tits, P. Demacker, A. Stalenhoef, 2000, Free radical biology & medicine.

Cholesteryl Ester Transfer Protein Inhibitor Torcetrapib and Off-Target Toxicity: A Pooled Analysis of the Rating Atherosclerotic Disease Change by Imaging With a New CETP Inhibitor (RADIANCE) Trials

D. Grobbee, J. Kastelein, M. Bots, 2008, Circulation.

Plasma proprotein convertase subtilisin kexin type 9 levels are related to markers of cholesterol synthesis in familial combined hyperlipidemia.

A. Isaacs, E. Schaefer, M. V. van Greevenbroek, 2013, Nutrition, metabolism, and cardiovascular diseases : NMCD.

Apolipoprotein B, non‐HDL cholesterol and LDL cholesterol for identifying individuals at increased cardiovascular risk

D. Swinkels, M. den Heijer, J. Graaf, 2010, Journal of internal medicine.

Brachial artery diameter is related to cardiovascular risk factors and intima‐media thickness

D. Swinkels, M. den Heijer, J. Graaf, 2009, European journal of clinical investigation.

Consumption of tall oil-derived phytosterols in a chocolate matrix significantly decreases plasma total and low-density lipoprotein-cholesterol levels.

J. Kastelein, A. Stalenhoef, J. de Graaf, 2002, The British journal of nutrition.

Transient bilateral cortical blindness as a presenting symptom of infective endocarditis.

J. V. D. van der Meer, A. Stalenhoef, J. Timmermans, 1996, The Netherlands journal of medicine.

Simvastatin in the effective reduction of plasma lipoprotein levels in familial dysbetalipoproteinemia (type III hyperlipoproteinemia).

P. Demacker, A. Stalenhoef, M. Mol, 1990, The American journal of medicine.

Differences in LDL receptor-mediated metabolism of three low density lipoprotein subfractions by human monocyte-derived macrophages: impact on the risk for atherosclerosis.

D. Swinkels, J. Hendriks, P. Demacker, 1993, Artery.

The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.

J. Borén, S. Humphries, M. Taskinen, 2014, The lancet. Diabetes & endocrinology.

Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline.

F. Sacks, M. Murad, A. Goldberg, 2012, The Journal of clinical endocrinology and metabolism.

Effect of aging and obesity on the expression of dyslipidaemia in children from families with familial combined hyperlipidaemia.

A. Stalenhoef, S. Bredie, J. de Graaf, 2007, Clinical science.

Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis.

A. Goldberg, I. Goldberg, A. Stalenhoef, 2014, Best practice & research. Clinical endocrinology & metabolism.

Original article Comparison of incidences of cardiovascular events among new users of different statins: a retrospective observational cohort study

S. Johansson, A. Stalenhoef, E. Heintjes, 2009 .

J. Borén, S. Humphries, M. Taskinen, 2014, European heart journal.

Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial.

M. Eriksson, J. Kastelein, M. Trip, 2010, Clinical therapeutics.

Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: a large cross-sectional study in The Netherlands.

J. Kastelein, B. Imholz, F. Visseren, 2010, Atherosclerosis.

A study of the chylomicron metabolism in WHHL rabbits after fat loading. Discrepancy between results based on measurement of apoprotein B-48 or retinyl palmitate.

P. Demacker, A. Stalenhoef, P. V. van Heijst, 1992, The Biochemical journal.

Chylomicrons in disease: a renaissance in lipidology International Symposium of Chylomicrons in Disease (ISCD), Lake Louise, Alberta, Canada, March 6th-8th, 2008.

G. Watts, A. Stalenhoef, 2008, Atherosclerosis. Supplements.

Answers to Questions Posed During Daily Patient Care Are More Likely to Be Answered by UpToDate Than PubMed

A. Stalenhoef, Arjen Hoogendam, P. F. D. V. Robbé, 2008, Journal of medical Internet research.

Association of fasting and nonfasting serum triglycerides with cardiovascular disease and the role of remnant-like lipoproteins and small dense LDL

A. Stalenhoef, J. de Graaf, 2008, Current opinion in lipidology.

Analysis of queries sent to PubMed at the point of care: Observation of search behaviour in a medical teaching hospital

Pieter de Vries Robbé, Arjen Hoogendam, Anton F. H. Stalenhoef, 2008, BMC Medical Informatics Decis. Mak..

The 4S Study

J. Slattery, J. McMurray, G. Thorgeirsson, 1994 .

Casus 34 – Antwoord

A. Stalenhoef, J. D. Graaf, 2012 .

Pregnancy in women suffering from familial hypercholesterolemia: a harmful period for both mother and newborn?

J. Kastelein, J. V. D. van der Post, A. Stalenhoef, 2009, Current opinion in lipidology.

Clinical Practice Guideline: Evaluation and Treatment of Hypertriglyceridemia: An Endocrine Society Clinical Practice Guideline

F. Sacks, M. Murad, A. Goldberg, 2012 .

Carotid and femoral artery wall thickness and stiffness in patients at risk for cardiovascular disease, with special emphasis on hyperhomocysteinemia.

G. Boers, H. Wollersheim, A. Stalenhoef, 1998, Arteriosclerosis, thrombosis, and vascular biology.

CHOLESTEROL SYNTHESIS INHIBITORS IN HYPERLIPIDAEMIA

A. Stalenhoef, M. Mol, P. Stuyt, 1988, The Lancet.

Casus 12 – Antwoord

A. Stalenhoef, J. D. Graaf, 2012 .